NKTR – nektar therapeutics (US:NASDAQ)
Stock Stats
News
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics (NASDAQ:NKTR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $102.00 price target on the stock.
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
How Recent Clinical Wins and Risks Are Changing the Story for Nektar Therapeutics [Yahoo! Finance]
Form 4 NEKTAR THERAPEUTICS For: Nov 21 Filed by: Zalevsky Jonathan
Form 4 NEKTAR THERAPEUTICS For: Nov 21 Filed by: Wilson Mark Andrew
Form 4 NEKTAR THERAPEUTICS For: Nov 21 Filed by: ROBIN HOWARD W
Form 144 NEKTAR THERAPEUTICS Filed by: ROBIN HOWARD W
Form 144 NEKTAR THERAPEUTICS Filed by: Wilson Mark Andrew
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.